Medicine developed at Ichilov moderates immune response, helps prevent deadly cytokine storm, researchers say; 29 of 30 phase 1 trial patients left hospital within 3-5 days
A new coronavirus treatment being developed at Tel Aviv’s Ichilov Medical Center has successfully completed phase 1 trials and appears to have helped numerous moderate-to-serious cases of COVID-19 quickly recover from the disease, the hospital said Friday.
Hailing a “huge breakthrough,” the hospital said Prof. Nadir Arber’s EXO-CD24 substance had been administered to 30 patients whose conditions were moderate or worse, and all 30 recovered — 29 of them within three to five days.
